Concepedia

Satoshi Tamada

ST

Statistics

Publications

45

Citations

5.9K

H-Index

25

Active since

2002

Affiliations

Osaka City University(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Queen Mary University of London

Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology

Palacký University Olomouc

Satoshi Tamada is an author at Osaka City University specializing in medicine, urology, and oncology.

ORCID

Top concepts

Publications per year

2002–2025

45

Publications

45

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · New England Journal of Medicine · 2019 · 3.3K citations · Full text

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Thomas Powles, Elizabeth R. Plimack, Denis Soulières et al. · The Lancet Oncology · 2020 · 721 citations

, , +6

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · Journal of Clinical Oncology · 2019 · 118 citations

, , +17

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

Elizabeth R. Plimack, Thomas Powles, V.P. Stus et al. · European Urology · 2023 · 118 citations

, , +9

1–5 of 45